Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP+

The cytoplasmic nuclear receptor RARγ controls RIP1 initiated cell death when cIAP activity is inhibited

(2017) Qing Xu et al.   Nature Communications

Lipophilic Cationic Cyanines Are Potent Complex I Inhibitors and Specific in Vitro Dopaminergic Toxins with Mechanistic Similarities to Both Rotenone and MPP+

(2016) Chamila C. Kadigamuwa et al.   CHEMICAL RESEARCH IN TOXICOLOGY

2, 2′- and 4, 4′-Cyanines are transporter-independentin vitrodopaminergic toxins with the specificity and mechanism of toxicity similar to MPP+

(2015) Chamila C. Kadigamuwa et al.   JOURNAL OF NEUROCHEMISTRY

The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death

(2015) Laleh Kamalian et al.   TOXICOLOGY IN VITRO

Binding-Induced Fluorescence of Serotonin Transporter Ligands: A Spectroscopic and Structural Study of 4-(4-(Dimethylamino)phenyl)-1-methylpyridinium (APP+) and APP+ Analogues

(2014) James N. Wilson et al.   ACS Chemical Neuroscience

APP+, a Fluorescent Analogue of the Neurotoxin MPP+, Is a Marker of Catecholamine Neurons in Brain Tissue, but Not a Fluorescent False Neurotransmitter

(2013) Richard J. Karpowicz et al.   ACS Chemical Neuroscience

Mitochondrial accumulation of a lipophilic cation conjugated to an ionisable group depends on membrane potential, pH gradient and pK a: implications for the design of mitochondrial probes and therapies

(2012) Peter G. Finichiu et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

4-(4-(Dimethylamino)phenyl)-1-methylpyridinium (APP+) Is a Fluorescent Substrate for the Human Serotonin Transporter

(2012) Ernesto Solis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the Progression of Parkinsons Disease

(2009) J. George et al.   Current Neuropharmacology

Mitochondrial Na+/Ca2+-Exchanger Blocker CGP37157 Protects against Chromaffin Cell Death Elicited by Veratridine

(2009) S. M. Nicolau et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics

(2009) Britta Haenisch et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

A review of Parkinson's disease

(2008) C. A. Davie   BRITISH MEDICAL BULLETIN

Vesicular Monoamine Transporter Substrate/Inhibitor Activity of MPTP/MPP+Derivatives: A Structure–Activity Study

(2008) D. Shyamali Wimalasena et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease

(2008) Patricia K. Sonsalla et al.   PARKINSONISM & RELATED DISORDERS